跳至主要内容
临床试验/EUCTR2018-004464-57-DE
EUCTR2018-004464-57-DE进行中(未招募)1 期

Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke - SWIFT DIRECT

niverstiy Hospital Bern0 个研究点目标入组 404 人开始时间: 2019年3月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
404

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Informed consent as documented by signature
  • -Age = 18 years
  • -Clinical signs consistent with an acute ischaemic stroke
  • -Neurological deficit with a NIHSS of = 5 and < 30 (deficits judged to be clearly disabling at presentation)
  • -Patient is eligible for IV t-PA
  • -Patient is eligible for endovascular treatment/therapy
  • -Randomization no later than 4 hours 15 minutes after stroke symptom onset and initiation of IV t-PA must be started within 4 hours 30 minutes of stroke symptoms onset (onset time is measured from the time when the subject was last seen well)
  • -Occlusion (mTICI 0-1) of the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, or both confirmed by CT or MR angiography, accessible for MT
  • -Core-infarct volume of Alberta Stroke Program Early CT Score (ASPECTS) greater than or equal to 4 (= 4) based on baseline CT or MR imaging (MRI) (a region has to have diffusion abnormality in 20% or more of its volume to be considered MR-ASPECTS positive)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 300
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 102

排除标准

  • Acute intracranial haemorrhage
  • Any contraindication for IV t-PA
  • Pre-treatment with IV t-PA
  • In-hospital stroke
  • Pregnancy or lactating women. A negative pregnancy test before randomization is required for all women with child-bearing potential.
  • Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys
  • Known current participation in a clinical trial
  • Renal insufficiency as defined by a serum creatinine > 2.0 mg/dl (or 176.8 µmol/l) or glomerular filtration rate (GFR) < 30 mL/min and /or known history of renal insufficiency or requirement for haemodialysis or peritoneal dialysis
  • Severe comorbid condition with life expectancy less than 90 days at baseline
  • Known advanced dementia or significant pre-stroke disability (mRS score of = 2)
  • Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad)
  • Comorbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments.
  • Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than four alcoholic drinks per day).
  • Known history of arterial tortuosity, pre-existing stent, other arterial disease and/or known disease at the femoral access site that would prevent the device from reaching the target vessel and/or preclude safe recovery after MT
  • Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma)
  • Radiological confirmed evidence of cerebral vasculitis
  • CTA or MRA evidence of carotid dissection
  • Evidence of additional distal intracranial vessel occlusion in another territory (i.e. A2 segment of anterior cerebral artery or M3, M4 segment of MCA) on initial NCCT/MRI or CTA/MRA

研究者

发起方
niverstiy Hospital Bern

相似试验